Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer: A Marker Based Phase II Trial

NCT04175470 is registered in ClinicalTrials.gov with Vejle Hospital as lead sponsor.

NCT NCT04175470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04175470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer: A Marker Based Phase II Trial
Lead sponsor
Vejle Hospital
Phase
Phase 2
Overall status
Completed
Start date
October 29, 2019
Completion date
December 31, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer recurrent